NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ:INSM) concerning possible violations of federal securities laws.
On June 8, 2016, Insmed announced that it had withdrawn a European marketing application submitted to the European Medicines Agency (“EMA”) for its drug ARIKAYCE. The Company stated that the marketing application was based on data from a mid-stage clinical study that “did not provide a sufficient amount of evidence to support an approval.” Insmed stated that the Company will resubmit the application when data is available from a later study. Following this news, shares of Insmed have fallen from a close of $12.01 per share on June 8, 2016, to a recent close of $9.73 per share on June 21, 2016. To obtain additional information about the investigation, go to:
or contact Eduard Korsinsky, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.